Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 XUYing-yi ¹ , ZHANGYa-ya ¹ , LUWei-feng ² ,  CHENYu-qiang ¹

1. Department of Oncology, Chenggong Hospital Affiliated to Xiamen University and No. 174 Hospital of PLA, Xiamen 361003, China;
2. Department of Vascular Surgery, Zhongshan Hospital, Xiamen University, Xiamen 361004, China;

Corresponding author：

CHENYu-qiang, Email: chenyq707@163.com

Keywords：

Osteopontin; Expression; Hepatocellular carcinoma; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20140228

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the association between expression of osteopontin (OPN) and Chinese population with hepatocellular carcinoma (HCC) and its clinical pathological characteristics. Methods Such databases including CBM, CNKI, VIP and WanFang Data were searched from inception to July 2014, for studies about the association between expression of OPN and Chinese population with HCC and its clinical pathological characteristics. Two reviewers independently screened literature according to the exclusion and inclusion criteria, extracted data, and assessed methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 case-control studies (involving 723 HCC cases and 102 controls) were included. The results of meta-analysis showed that:OPN expression was higher in HCC group than normal control group (OR=10.25, 95%CI 6.13 to17.14); and higher in imperfect capsular infiltration group than perfect capsular infiltration group (OR=2.71, 95%CI 1.58 to 4.64). However, no significant difference was found in OPN expression between isolated tumour group and multiple tumours group (OR=0.95, 95%CI 0.56 to 1.62); between high differentiation group and low differentiation group (OR=0.60, 95%CI 0.36 to 1.01); and between clinical stages I-Ⅱ group and clinical stages Ⅲ-IV group (OR=0.93, 95%CI 0.53 to 1.63). Conclusion Current evidence shows that OPN may take part in the whole course (occurrence and advance) of HCC in Chinese population, but the problem whether it can be used as a factor to evaluate prognosis needs to be further studied.

Citation： XUYing-yi, ZHANGYa-ya, LUWei-feng, CHENYu-qiang. Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(12): 1418-1423. doi: 10.7507/1672-2531.20140228 Copy

1.	李征, 米登海, 杨克虎, 等.介入化疗栓塞术联合热疗治疗原发性肝癌的Meta分析.中国循证医学杂志, 2012, 12(6):672-678.
2.	沈蔚, 张家敏, 毛根军, 等. OPN和MMP-2在肝癌的表达及临床意义.实用肿瘤学杂志, 2008, 22(5):437-438.
3.	林帆, 李瑜元, 温敏杰, 等.骨桥蛋白在肝细胞癌中的表达及其临床病理意义.中华生物医学工程杂志, 2009, 15(3):216-219.
4.	刘兵团, 张国新, 郝波, 等.骨桥蛋白在肝癌患者外周血和癌组织中的含量及其临床意义.苏州医药, 2007, 33(11):1081-1083.
5.	姜伟栋, 印芳颖, 张明威, 等.原发性肝癌组织中骨桥蛋白与MMP-2的表达及临床意义.临床肝胆病杂志, 2006, 22(6):439-441.
6.	张岚, 李海玉, 殷晓璐, 等.骨桥蛋白下游信号分子在肝细胞癌中的表达.中华肝脏病杂志, 2011, 19(1):48-51.
7.	刘秀峰, 施瑞华, 张国新, 等. OPN和Syndecan-1在原发性肝癌中的表达及与临床病理参数之间的相关性.世界华人消化杂志, 2007, 15(16):1800-1805.
8.	郜玉峰, 李旭, 谢琴秀, 等.骨桥蛋白和CD44v6在肝癌中的表达及意义.中华肝脏病杂志, 2005, 13(3):227-228.
9.	曾文, 刘青光, 姚英民.骨桥蛋白、甲胎蛋白表达与原发性肝癌的关系.中国普通外科杂志, 2007, 16(8):806-808.
10.	万幼峰, 许英艺, 张雅雅, 等.肝癌组织中骨桥蛋白的表达与临床病理因素的相关性研究.临床军医杂志, 2012, 40(2):376-378.
11.	陆健, 卞建民, 时开网, 等.肝细胞癌组织中骨桥蛋白的表达及其与血管生成的关系.山东医药, 2006, 46(9):3-5.
12.	Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomized studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
13.	李泽文, 周洁, 何源萍, 等.喉癌组织中Survivin表达及其临床意义的Meta分析.中国循证医学杂志, 2013, 13(10):1200-1208.
14.	Wai PY, Kuo PC. The ro1e of Osteopontin in tumor metastasis. J Surg Res, 2004, 121(2):228-241.
15.	Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1):184-190.
16.	Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis associated protein osteopontin in human breast cancer. Cancer Res, 2002, 62(12):3417-3427.
17.	高伟, 司雁菱, 吴瑜.骨桥蛋白、PTEN蛋白和C-met跨膜蛋白在肝细胞癌中的表达及意义.中国临床医学, 2009, 16(3):377-379.
18.	武金才, 孙冰生, 刘道永, 等.比较基因组杂交芯片技术对肝癌组织中骨桥蛋白不同表达肿瘤细胞基因组的研究.中华肝胆外科杂志, 2008, 14(12):854-857.
19.	魏少峰, 郜玉峰, 李旭, 等.骨桥蛋白和P21在原发性肝癌中的表达及其临床意义.实用肝脏病杂志, 2005, 8(2):73-76.
20.	陈发龙, 陈军, 曾丽.骨桥蛋白与MMP-9在肝细胞癌中的表达及其临床意义.中国肿瘤临床, 2007, 34(20):1160-1163.
21.	陈荣新, 叶胜龙, 李涛, 等.骨桥蛋白在不同转移潜能肝癌细胞系及肝癌组织中表达意义.中华肝胆外科杂志, 2009, 15(4):279-282.

1. 李征, 米登海, 杨克虎, 等.介入化疗栓塞术联合热疗治疗原发性肝癌的Meta分析.中国循证医学杂志, 2012, 12(6):672-678.
2. 沈蔚, 张家敏, 毛根军, 等. OPN和MMP-2在肝癌的表达及临床意义.实用肿瘤学杂志, 2008, 22(5):437-438.
3. 林帆, 李瑜元, 温敏杰, 等.骨桥蛋白在肝细胞癌中的表达及其临床病理意义.中华生物医学工程杂志, 2009, 15(3):216-219.
4. 刘兵团, 张国新, 郝波, 等.骨桥蛋白在肝癌患者外周血和癌组织中的含量及其临床意义.苏州医药, 2007, 33(11):1081-1083.
5. 姜伟栋, 印芳颖, 张明威, 等.原发性肝癌组织中骨桥蛋白与MMP-2的表达及临床意义.临床肝胆病杂志, 2006, 22(6):439-441.
6. 张岚, 李海玉, 殷晓璐, 等.骨桥蛋白下游信号分子在肝细胞癌中的表达.中华肝脏病杂志, 2011, 19(1):48-51.
7. 刘秀峰, 施瑞华, 张国新, 等. OPN和Syndecan-1在原发性肝癌中的表达及与临床病理参数之间的相关性.世界华人消化杂志, 2007, 15(16):1800-1805.
8. 郜玉峰, 李旭, 谢琴秀, 等.骨桥蛋白和CD44v6在肝癌中的表达及意义.中华肝脏病杂志, 2005, 13(3):227-228.
9. 曾文, 刘青光, 姚英民.骨桥蛋白、甲胎蛋白表达与原发性肝癌的关系.中国普通外科杂志, 2007, 16(8):806-808.
10. 万幼峰, 许英艺, 张雅雅, 等.肝癌组织中骨桥蛋白的表达与临床病理因素的相关性研究.临床军医杂志, 2012, 40(2):376-378.
11. 陆健, 卞建民, 时开网, 等.肝细胞癌组织中骨桥蛋白的表达及其与血管生成的关系.山东医药, 2006, 46(9):3-5.
12. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomized studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
13. 李泽文, 周洁, 何源萍, 等.喉癌组织中Survivin表达及其临床意义的Meta分析.中国循证医学杂志, 2013, 13(10):1200-1208.
14. Wai PY, Kuo PC. The ro1e of Osteopontin in tumor metastasis. J Surg Res, 2004, 121(2):228-241.
15. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1):184-190.
16. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis associated protein osteopontin in human breast cancer. Cancer Res, 2002, 62(12):3417-3427.
17. 高伟, 司雁菱, 吴瑜.骨桥蛋白、PTEN蛋白和C-met跨膜蛋白在肝细胞癌中的表达及意义.中国临床医学, 2009, 16(3):377-379.
18. 武金才, 孙冰生, 刘道永, 等.比较基因组杂交芯片技术对肝癌组织中骨桥蛋白不同表达肿瘤细胞基因组的研究.中华肝胆外科杂志, 2008, 14(12):854-857.
19. 魏少峰, 郜玉峰, 李旭, 等.骨桥蛋白和P21在原发性肝癌中的表达及其临床意义.实用肝脏病杂志, 2005, 8(2):73-76.
20. 陈发龙, 陈军, 曾丽.骨桥蛋白与MMP-9在肝细胞癌中的表达及其临床意义.中国肿瘤临床, 2007, 34(20):1160-1163.
21. 陈荣新, 叶胜龙, 李涛, 等.骨桥蛋白在不同转移潜能肝癌细胞系及肝癌组织中表达意义.中华肝胆外科杂志, 2009, 15(4):279-282.

Chinese Journal of Evidence-Based Medicine

Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content